Should We Look East For Biopharma’s Next R&D Engine?

As 2025 begins, the pharma industry is abuzz with discussions on pipeline strategies and China's growing role. With 30% of large pharma licensing deals now involving Chinese biotech, we take a whistlestop tour of the companies and regions driving this innovation.